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Abstract: HE4, also known as WFDC2, is a useful biomarker for ovarian cancer when 
either used alone or in combination with CA125. HE4 is also overexpressed in endometrial 
cancer (EC), but its function in cancer cells is not clear. In this study, we investigate the 
role of HE4 in EC progression. An HE4-overexpression system was established by cloning 
the  HE4  prototypic  mRNA  variant  (HE4-V0)  into  a  eukaryotic  expression  vector. 
Following transfection, stable clones in two EC cell lines were selected. The effects of 
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HE4  overexpression  on  cell  growth  and  function  were  measured  with  the  use  of  cell 
proliferation  assay,  matrigel  invasion,  and  soft  agar  gel  colony  formation  assays.  
HE4-induced cancer cell proliferation in vivo was examined in a mouse xenograft model. 
HE4 overexpression significantly enhanced EC cell proliferation, matrigel invasion, and 
colony formation in soft agar. Moreover, HE4 overexpression promoted tumor growth in 
the mouse xenograft model. HE4 overexpression enhanced several malignant phenotypes 
in  cell  culture  and  in  a  mouse  model.  These  results  are  consistent  with  our  previous 
observation that high levels of serum HE4 closely correlate with the stage, myometrial 
invasion  and  tumor  size  in  patients  with  EC.  This  study  provides  evidence  that  HE4 
overexpression directly impacts tumor progression in endometrial cancer.  
Keywords:  endometrial  cancer;  human  epididymis  protein  4  (HE4);  HE4  variant; 
proliferation; invasion; colony formation; tumorigenesis 
 
1. Introduction  
National Cancer Institute (NCI) statistics show that while there was an insignificant decline in the 
incidence  of  endometrial  cancer  (EC)  from  1997  to  2006  (−0.4  annual  percentage  change),  the 
mortality rate increased significantly in the same time period (+0.3 annual percentage change). These 
data seem to suggest a trend for an increasing frequency of more aggressive forms of EC in the United 
States [1], which underscores the need for a better understanding of the molecular mechanisms and 
pathways involved in EC pathogenesis.  
We performed a proteomics analysis on EC patient samples and found that HE4, a putative protease 
inhibitor containing two WAP (Whey Acid Protein) domains [2–4], is significantly increased in the 
endometrioid subtype of EC. Tissue microarray and real-time PCR studies confirmed a high level of 
HE4 expression in both endometrioid and serous types of EC [5]. These results are consistent with 
those from other laboratories showing increased HE4 mRNA and protein expression in endometrial 
cancer tissues [6–10]. Our subsequent investigation demonstrated that while all the five HE4 mRNA 
variants (or isoforms) are detectable in various normal tissues with varying expression levels, their 
levels  are  significantly  increased  in  EC  compared  to  normal  endometrium.  Moreover,  regression 
analysis indicated that the expression levels of HE4-V1, HE4-V3 and HE4-V4 closely correlate with 
patients’ disease-free survival [5]. In a recent study in breast cancer tissues, Kamei et al. demonstrated 
that,  HE4  expression  levels  are  associated  with  both  the  lymph  node  metastases  and  decreased  
disease-free survival [11]. Furthermore, we observed that increased HE4 serum levels are associated 
with poor prognostic factors such as higher disease stage and deep myometrial invasion [5]. Taken 
together, these findings suggest that the function of HE4 may be directly involved in carcinogenesis. 
Interestingly, chromosome 20q, the region harboring the genes for HE4 and several WAP domain 
factors, is known to be a hot spot for frequent genetic amplification in EC, providing a potential 
mechanism that might be responsible for increased HE4 expression [12,13].  
HE4,  also  designated  as  WFDC2  (WAP  four-disulfide  core  domain  2),  is  a  secretory  protein 
detectable in human serum  [3,14,15]. Correspondent to its overexpression in cancers arising from Int. J. Mol. Sci. 2013, 14  6028 
 
ovarian and endometrial [6–8], breast [11], and lung [2,6] tissues, HE4 serum levels are elevated in 
these  cancer  patients  [3,10,14,16–18].  Most  previous  HE4  studies  have  concentrated  on  the 
development and improvement of the serum detection assay, as well as the clinical application of the 
HE4 test for ovarian cancer diagnosis, prognosis, and triage of patients with pelvic masses [16–26] 
These studies have shown that serum HE4 levels, alone or in combination with additional tests such as 
CA125, provide superior specificity and sensitivity to CA125 alone, or with other biomarkers [27]. 
Despite  this  progress,  the  cellular  function  of  HE4,  specifically  its  potential  role(s)  in  cancer 
development, has not been systematically investigated. It is noteworthy that accumulated data has 
implicated WAP domain family members in cancer pathogenesis. Elafin and SLPI (secreted leukocyte 
protease inhibitor, or anti-leukoproteinase 1) are the two best-studied WAP proteins known to possess 
anti-protease activities. Elafin is expressed in human squamous cell carcinoma of the lung, but not in 
normal bronchial epithelium [28]. The immunostaining score of elafin was shown to be positively 
correlated with the squamous cell differentiation in head and neck, as well as esophageal tumors [29]. 
Clauss et al. have also shown that Elafin is overexpressed in serous ovarian cancer and correlated with 
poor overall survival [30]. SLPI is upregulated in a highly metastatic breast cancer cell line  [31]. 
Immunohistochemistry studies on primary cancer tissues indicated a close association between SLPI 
levels and lymph node involvement [31]. Moreover, stable transfection experiments demonstrated that 
overexpression of either mouse or human SLPI led to increased tumorigenicity and lung-colonization 
potential of a low grade breast cancer cell line [32]. The prototypic HE4 protein contains two WAP 
domains that share some similarities with those from other WAP family members [33]. The prototype 
HE4 is encoded by a HE4 mRNA variant (NM_006103.3, HE4-V0) that is found at the highest levels 
in  benign  endometrium  and  EC  tissues  [5].  In  this  study,  we  chose  to  concentrate  on  the 
characterization of the HE4 effect on the malignant phenotypes of EC and the in vivo development of 
EC in a mouse xenograft model. 
2. Results 
2.1. Overexpression of Human HE4 in Endometrial Cancer Cell Lines 
Two endometrial cancer cell lines, HEC-1B containing relatively lower endogenous HE4 levels and 
Ark2  with  relative  higher  endogenous  HE4  levels  (data  not  shown),  were  transfected  with  
pcDNA 3.1-Myc-His-HE4 to achieve ectopic overexpression of HE4. Following transient transfection, 
HE4 protein levels were determined by real-time PCR and Western blot analysis (Figure 1A). The 
results confirmed that transfection with the HE4 construct was able to deliver HE4 overexpression in 
both cell lines. Stable transfection was subsequently performed and stable clones were selected using 
geneticin. HE4 levels in these clones were measured by real-time PCR (data not shown) and Western 
blot analysis. The four HEC-1B (HEC-1B-HE4-C4, -C5, -C11 and -C12) (Figure 1B) and four Ark2 
(Ark2-HE4-C3, -C7, -C9 and -C12) (Figure 1C) clones with HE4 overexpression were selected. As 
previously reported by Drapkin, et al., in the HEC-1B-HE4-C12 clone, the HE4 antibody detected two 
bands with different migration rates, a phenomenon most likely caused by differential glycosylation 
modification of HE4 [4]. The HE4 positive clones and control clones (HEC-1B-PC5 and -PC10 for Int. J. Mol. Sci. 2013, 14  6029 
 
HEC-1B cells; Ark2-PC1 and -PC2 for Ark2 cells) were stored and subsequently used for studies on 
HE4 function.  
Figure 1. HE4 overexpression in EC cell lines. (A) Confirmation of HE4 overexpression 
following transient transfection. Ark2 cells were transfected with pcDNA 3.1-His-HE4 and 
the control plasmid pcDNA 3.1, respectively. Anti-HE4 and anti-His antibodies were used 
for Western blot analysis. A dramatically increased level of HE4 protein was detected in 
pcDNA  3.1-His-HE4  transfected  cells.  The  same  blot  was  detected  with  an  antibody 
against β-actin and the result was used as protein loading control; (B,C) Confirmation of 
HE4  overexpression  in  stable  clones.  HEC-1B  and  Ark2  cells  were  transfected  with 
pcDNA 3.1-His-HE4 and the control  plasmid pcDNA 3.1. Stable clones  were selected 
using  geneticin  and  HE4  overexpression  was  examined  by  Western  blot  analysis.  In  
HEC-1B cells (B), increased HE4 protein levels were found in HEC-1B-HE4-C4, -C5,  
-C11 and -C12 clones compared to the HEC-1B-PC5 and -PC10 control clones. In Ark2 
cells (C), increased HE4 protein levels were detected in Ark2-HE4-C3, -C7, -C9, and -C12 
clones over the Ark2-PC1 and -PC2 control clones.  
 
2.2. HE4 Overexpression Stimulates Endometrial Cancer Cell Growth 
Altered  cell  proliferation  represents  a  malignant  feature  that  potentially  contributes  to  cancer 
progression. To ascertain the effect of HE4 upregulation on HEC-1B and Ark2 cellular proliferation,
 
the tetrazolium colorimetric cell proliferation assay was performed and the growth curves were shown 
in Figure 2. Compared to control cells, HEC-1B cells (HEC-1B-HE4-C4, -C5 and -C12 clones) with Int. J. Mol. Sci. 2013, 14  6030 
 
the highest levels of HE4 grew fastest, while HEC-1B-HE4-C11 expressing limited or lower levels of 
HE4 exhibited no significant change in proliferation. The population doubling time decreased from 
2.21 days in control cells to 1.68 days, 1.76 days and 1.69 days for the HEC-1B-HE4-C4, -C5 and  
-C12  clones,  respectively  (Figure  2).  Interestingly,  HEC-1B-HE4-C4  and  -C5  clones  contain 
comparable levels of HE4 protein, and the two clones showed similar cell growth rates, although the 
HE4 protein migration rate was different (Figure 1A), suggesting the possibility that cell proliferation 
may not be closely related to HE4 protein posttranslational modification-glycosylation. Similar results 
were observed in Ark2 cell lines (data not shown). Since no significant change in either basal or 
inducer (cycloheximide or camptothecin)-mediated cell apoptosis was observed in HE4-overexpressing 
cells (data not shown), HE4 effects on cell proliferation appeared to be mostly due to an effect on the 
cell cycle. The positive impact of HE4 on cell proliferation in cell culture points to a potential role of 
HE4 for in vivo endometrial cancer growth. 
Figure 2. Cell proliferation assay in EC cells. (A) HEC-1B HE4 stable transfection clones 
(HEC-1B-HE4 C4, -C5, -C11, -C12) and control (-PC10) clone were grown in 48-well 
plates. The absorbance values were expressed as a ratio of Day 1 to 4 versus day 0 (set as 
1). Growth curves show the relative absorbance at different time points (left panel). The 
ratios were converted to a logarithmic scale and the cell population doubling time (PDT) 
was calculated using the linear regression model (right panel). The HE4-overexpressing 
clones (HEC-1B-HE4-C4, -C5 and -C12) grew significantly faster from day 2 to Day 4  
(p  <  0.05, marked by *) and had shorter PDT than the PC10 control cells. Proliferation 
assay  was  also  performed  in  Ark2  cells  (B).  As  shown  in  the  growth  curves,  the  
HE4-overexpressing  clone  (Ark2-HE4-C3)  grew  faster  than  the  PC-1  control  cells  
(p < 0.05, marked by *).  
 
 Int. J. Mol. Sci. 2013, 14  6031 
 
2.3. HE4 Overexpression Enhances Invasive Ability and Anchorage-Independent Growth in EC Cells  
Matrigel invasion and anchorage-independent growth in soft agar are characteristics of malignant 
phenotypes found in various cancer cells. Figure 3 shows representative microscope fields for each of 
the  stable clones  and the cell counting results  from the matrigel  invasion assay. More cells  from  
HE4-overexpressing clones (Ark2-HE4-C3 and -C7) invaded through the transwell compared to the 
Ark2-PC1 control clone. No significant change in the invasion ability was observed in the Ark2-HE4-C9 
clone  that  expressed  relatively  low  levels  of  HE4.  A  similar  effect  by  HE4  overexpression  was 
observed in HEC-1B cells (data not shown).  
Figure 3. Effects of HE4 on EC cell invasion capability. HE4-overexpressing and control 
clones were subjected to matrigel invasion assay. The experiments were repeated three 
times, and one representative result is shown in the upper panel. Cell counting showed a 
significant increase of invasion activity (in light purple color, as indicated by arrows) in 
HE4-overexpressing Ark2-HE4-C3 and -C7 clones than in the Ark2-PC1 control clone  
(p < 0.05, marked by *, lower panel). 
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The Transformation Detection Assay was performed according to the manufacturer’s protocols to 
examine anchorage-independent growth. As shown in Figure 4A, colonies were formed at different 
depths in the soft agar. The number of colonies from 10 randomly selected microscopic fields was 
counted and an average colony number for each group was shown in Figure 4B. HE4-overexpressing 
clones grew significantly more colonies than the control clones. Similar results were also obtained in 
the Ark2 EC cell line (data not shown). Overall, these results suggest that HE4 overexpression was 
able to confer a more malignant phenotype in EC cells. 
Figure  4.  HE4  overexpression  affects  colony  formation  in  soft  agar.  Control  
(HEC-1B-PC10) and HE4-overexpressing clones (HEC-1B-HE4-C4) were cultured in top 
soft agar for 22 days. (A) a representative result under low magnification, showing that 
colonies  (stained in  brown color)  formed at  the different  depths  of soft agar;  (B) The 
average number of colonies and standard error for the two groups were calculated based on 
three independent experiments. The HE4-overexpressing cells formed significantly more 
colonies compared to control cells (p < 0.01).  
 
 
2.4. HE4 Overexpression Promotes EC Tumor Growth in Vivo 
Following the positive results from in vitro experiments, we further examined the effects of HE4 
overexpression  using  a  mouse  xenograft  model.  The  mixture  of  HE4-overexpressing  clones  and  
HEC-1B control clones were injected into SCID mice. Tumor growth curves were constructed by 
plotting tumor volumes against time (Figure 5, top panel). Tumors formed from HE4-overexpressing 
cells exhibited accelerated growth compared to the control cells. On the 30th day, the mice were 
sacrificed, and tumors were dissected and weighed (Figure 5, middle panel). Average tumor weights Int. J. Mol. Sci. 2013, 14  6033 
 
were compared between the two groups (Figure 5, lower panel). Consistent with the growth curves, the 
average final tumor weight from HE4-overexpressing cells was almost 3-fold heavier than that from 
the control cells. This effect is unlikely due to the artifact caused by clonal selection since a mixture of 
clones was used and a similar effect of HE4 overexpression was also observed when the Ark2 stable 
clones were injected to the SCID mice (data not shown).  
Figure 5. Effect of HE4-overexpression on xenograft tumor growth rate. HEC-1B HE4 
overexpression and control clones were mixed, respectively, and inoculated subcutaneously 
into  8  SCID  mice.  Top  panel:  Growth  curves  showed  that  tumors  formed  by  
HE4-overexpressing cells grew faster than those by control cells. Middle panel: Tumors 
were dissected from mice on the 30th day. Bottom panel: Dissected tumors were weighed. 
The average weights and standard errors were calculated for each group. HE4-overexpressing 
cells grew tumors approximately three times larger than control cells (* p < 0.05). 
 
 
2.5. Determination of HE4 mRNA and Protein Levels in EC Tumor Tissues 
Total HE4 mRNA isolated from tumor tissues dissected from the xenograft model was measured. 
Real-time  PCR  results  confirmed  that  tumors  grown  from  HE4-overexpressing  cells  contained  a 
significantly  higher  HE4  mRNA  level  than  the  tumors  from  control  cells  (data  not  shown). Int. J. Mol. Sci. 2013, 14  6034 
 
Immunohistochemistry using specific antibody against human HE4 confirmed, in accordance with the 
results from the mRNA measurement, that higher levels of HE4 were present in tumors derived from 
the HE4-overexpressing cells than those from control cells using Wilcoxon signed-rank test analysis  
(Z  =  −2.232,  p  =  0.026  (2-tailed),  SPSS  Software  Version  19,  IBM,  New  York,  NY,  USA). 
Representative images are shown in Figure S1. These results confirmed the continuing overexpression 
of HE4 mRNA and protein in vivo in the cells engineered for HE4 overexpression.  
2.6. Tumors Overexpressing HE4 Have a Higher Number of Cells in the S-Phase 
We  performed  immunohistochemistry  analyses  on  the  tumor  samples  to  examine  if  HE4 
overexpression  can  impact  tumor  cell  proliferation.  Cells  in  S-phase  were  detected  in  the  
paraffin-embedded tumor tissues by immunostaining with BrdU antibodies. Representative fields of 
BrdU  staining  were  shown  in  Figure  6A.  The  HE4-overexpressing  tumors  derived  from  
HE4-overexpressing clones contained a higher average of BrdU-positive cells than those from the 
control clones (p < 0.05) (Figure 6B). This result confirmed the positive effects of HE4 overexpression 
on  cell  proliferation.  Thus,  the  larger  tumor  mass  following  HE4  overexpression  may  be  mostly 
accounted for by the enhancement of cell cycling.  
Figure  6.  Tumor  cell  proliferation  in  xenografts.  In  vivo  BrdU  incorporation  and 
immunostaining assays were performed in mice xenografts. (A) Representative staining 
results from the control and HE4-overexpressing groups; (B) The BrdU-positive (brown 
color) and negative nuclei were counted and the percentage of positive nuclei in  total 
nuclei  was  calculated.  Tumors  from  HE4-overexpressing  cells  contain  a  significantly 
higher percentage of BrdU-positive nuclei than tumors from control cells (p < 0.05). 
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3. Discussion 
We have observed that five HE4 alternatively spliced variants are expressed in benign endometrial 
tissues, and that all of them are significantly increased in both type I and type II EC [5]. Moreover, 
HE4  serum  levels  are  closely  correlated  with  EC  stage,  myometrial  invasion,  and  primary  tumor 
diameter [5]. These findings suggest a potential role of HE4 in EC development. In this study, we 
employed cell cultures and animal models to characterize HE4 effects on EC malignant phenotypes, 
and  we  found  that  HE4  overexpression  resulted  in  increased  cancer  cell  proliferation,  invasion 
capability, and anchorage independent growth. In vivo experiments indicated that HE4 overexpression 
promotes the EC xenograft growth in SCID mice. Thus, rather than being the byproducts of cancer 
cells  and  considered  a  surrogate  marker  for  aggressive  malignancies,  HE4  may  function  as  an 
oncogenic  or  tumor-promoting  factor  for  EC  development.  To  our  knowledge,  this  is  the  first 
experimental evidence in support of a tumor-promoting role of HE4. We should point out that while 
our  data  reveal  a  potentially  important  function  of  HE4,  the  detailed  molecular  pathways/mechanisms 
regarding its upregulation and tumor-promoting actions during EC development remains unknown. 
Also, as an initial attempt to investigate HE4 function, our study has focused on the characterization of 
HE4-V0,  the  prototype  HE4  variant  expressed  at  the  highest  levels  in  human  tissues.  In  normal 
endometrium, levels of HE4-V0 are 50-, 200-, 75-, and 143-fold higher than the levels of other four 
variants: HE4-V1, HE4-V2, HE4-V3, and HE4-V4, respectively [5] Follow-up investigations using a 
similar  approach  may  help  our  understanding  on  the  function  of  other  HE4  variants  in  
EC pathogenesis.  
There appears to be overall agreement among our findings and those from our other two studies, 
ranging from cell culture, xenograft experiments, to clinical data regarding the HE4 expression and 
function. For example, cells expressing higher levels of HE4 exhibited faster proliferation than cells 
expressing lower levels of HE4. Correspondently, cells containing high levels of HE4 grew larger 
tumors than those with low HE4 expression in mouse xenografts. Clinical studies showed that high 
HE4 serum levels were correlated with later EC stage and larger primary tumor mass [34]. Similarly, 
we demonstrated that HE4 overexpression increases the ability of tumor cells to invade the matrigel, 
while higher HE4 serum levels were found to be associated with a greater tendency for myometrial 
invasion [34]. Interestingly, Kamei et al. performed HE4 immunohistochemistry on surgical specimens 
from breast cancer patients and found that lymph node metastases were associated with high HE4 
expression [11]. Lymph node metastasis represents an important route for endometrial carcinomas, and 
lymph node involvement is a critical predictor of reduced survival. Unfortunately, our subcutaneous 
mouse xenograft model was not appropriate for investigating lymphatic spread, and future studies 
using a mouse uterine orthotopic model would be necessary to investigate this issue.  
Studies from this and other laboratories indicate that HE4 mRNA and proteins were elevated in EC 
cells compared to normal endometrial glandular cells [5,6–8,10,35,36]. This provides the rationale for 
the use of an overexpression, rather than knockdown, approach to investigate HE4 function. Moreover, 
quantitative  correlations  between  HE4  expression  levels  and  functional  data  as  observed  in  cell 
proliferation and cell invasion experiments suggest a dose-response effect for HE4 in EC cells. Our 
conclusion regarding the significant role of HE4 in EC cells is further strengthened by the consistency 
of the results from both the HEC-1B and Ark2 EC cell lines. It should be noted that cancer is a Int. J. Mol. Sci. 2013, 14  6036 
 
multistep  process  and  different  sets  of  genetic  and  epigenetic  changes  are  involved  in  various  
steps  [37,38].  Tumorigenesis,  an  early  event  associated  with  malignant  transformation,  and  tumor 
growth promotion, a process more closely associated with tumor growth and metastasis, are thought to 
be  two  related—but  largely  different—processes  [37].  Some  tumorigenic  factors  contribute  to 
malignant transformation, but not necessarily tumor growth and/or metastasis, and vice versa. Since 
our in vitro studies were all performed in cancer cell lines, the results are not informative regarding the 
role of HE4 in malignant transformation. Similarly, while the mouse xenograft model utilized in this 
investigation is reliable and convenient, the EC cells are readily tumorigenic in SCID mice and are 
therefore not suitable for determining if HE4 is tumorigenic in vivo. The HE4 transgenic mouse model 
may be useful for characterization of the carcinogenesis-specific role of HE4. Although we have used 
“tumor-promoting” to describe the overall effects of HE4 overexpression on EC cell proliferation and 
other malignant phenotypes, we recognize the non-specific and imprecise nature of this term. Without 
knowledge on the specific molecular mechanisms of HE4 action, it is not clear if HE4 affects tumor 
apoptosis, regulates the cell cycle, or encourages metastasis. Future studies concentrating on the HE4 
protease  inhibitor  activity,  the  relationship  between  this  activity  and  cell  cycle  regulation,  and  
protein-protein  interaction  may  help  to  elucidate  the  molecular  pathways  mediating  the  HE4  
tumor-promoting activity.  
The HE4 tumor-promoting activities appear similar to those found in other WAP proteins, namely 
elafin and SLPI. For those factors, the role in cancer development was thought to be related to their 
inhibitory  effects  on  protease  activity.  However,  additional  functions,  unrelated  to  anti-protease 
activity,  have  also  been  documented  by  some  studies.  For  example,  SLPI  is  capable  of  blocking 
activation of the NF-κB signaling pathway induced by lipopolysaccharide, which is unlikely to be 
related to protease inhibition [39]. Moreover, SLPI has anti-HIV activity, which is dependent not on its 
anti-protease  activity  but  rather  on  its  high  affinity  binding  to  the  cell  surface  components  of 
monocytes [40]. Thus, WAP domain factors may be capable of triggering signaling pathways [12] that 
regulate multiple downstream targets. Amino acid sequence-based bioinformatic analysis suggests that 
the WAP domains of HE4-V0 differ significantly from those of elafin and SLPI [33], and HE4-V0 is 
unlikely to carry any protease inhibitor activity. This observation suggests that the HE4 tumor-promoting 
function may not be mediated by a protease inhibition. Mutagenesis-directed sequence substitution and 
deletion studies are required to determine if the WAP domains are involved in the tumor-promoting 
activity of HE4.  
Genetic and hormonal alterations are considered two major etiological factors for EC development. 
Many oncogenes achieve a high level of expression via genetic amplification. In humans, HE4, SLPI, 
and several other WAP members co-locate in 20q12-13 [12], a region frequently amplified in a variety 
of cancers [41]. Using comparative genomic hybridization (CGH), Micci et al. showed that gain of 20q 
was a frequent chromosomal abnormality in endometrial carcinomas [13]. These results suggest that 
somatic gain of genetic material may be a mechanism by which HE4 is expressed in high levels in 
endometrial cancer cells. Endometrium is also subject to tight control of both peptide and steroid 
hormone synthesis by changes in either hormonal levels or their receptors, and this may also contribute 
to the high HE4 levels as observed in endometrial cancer cells.  
In summary, forced overexpression of HE4 promotes several malignant phenotypes including cell 
proliferation, cell invasion capability, anchorage independent growth, and increased tumor growth in Int. J. Mol. Sci. 2013, 14  6037 
 
endometrial  cancer  xenograft.  Thus,  the  upregulated  HE4  levels  observed  in  primary  endometrial 
cancer tissues may contribute to EC progression. Further studies are required to establish the molecular 
mechanisms responsible for the tumorigenic and tumor-promoting actions of HE4 in a variant-specific 
manner, and to understand the events leading to HE4 upregulation. 
4. Experimental Section 
4.1. Cell Culture 
Ark2 and HEC-1B cells were purchased from ATCC and grown in RPMI1640 and DMEM/F12 
medium,  respectively.  Both  media  were  supplemented  with  fetal  bovine  serum  (10%  FBS)  and 
antibiotics. Cells were grown to 50%–70% confluence before used for experiments. 
4.2. Construction of Plasmid Vectors  
The full-length  coding region of human HE4 was  generated by PCR using the following PCR 
primers: HE4 forward primer: 5'-CG GGA TCC ATG CCT GCT TGT CGC CTA GGC; HE4 reverse 
primer: 5'-GC GAA TTC G AAA TTG GGA GTG ACA CAG. The cDNA fragment was subcloned 
into the pcDNA3.1-His-myc-A vector (Invitrogen, Carlsbad, CA, USA). His-tag and myc-tag epitopes 
were  incorporated  to  the  N-terminus  of  HE4  peptide.  Positive  clones  were  confirmed  by  DNA 
sequencing at the Mayo Clinic Biochemistry Core Facility.  
4.3. RNA Isolation and Reverse Transcription 
Total RNA from EC and normal endometrium was isolated from 10-μm sections of frozen tissues 
using Trizol Reagent (Invitrogen, Carlsbad, CA,  USA). Total RNA from EC cell lines was isolated 
according to the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) protocol. All the RNA was treated 
with DNase I (30 Units/sample) to remove genomic DNA contamination. cDNA was synthesized with 
1 μg of total RNA using the SuperScript™ kit (Invitrogen, Carlsbad, CA, USA) in 20-μL reactions. 
Reaction  mixtures  cDNA  were  diluted  to  100  μL,  and  1  to  3  μL  was  used  for  each  real-time  
PCR reaction.  
4.4. Real-Time PCR Analyses of mRNA Levels 
Real-time PCR was performed using the Cyber Green PCR Master Mix (Invitrogen, Carlsbad, CA, 
USA) as previously described [42] using the following primers: HE4-Forward: 5'-ATA GCA CCA 
TGC CTG CTT GT; HE4-Reverse: 5'-TGC TCC TGT GCC TGA GAC TA. Housekeeping gene 36B4 
was  used  as  an  internal  reference:  36B4-Forward:  5'-ATG  CAG  CAG  ATC  CGC  ATG  T;  
36B4-Reverse:  5'-TCA  TGG  TGT  TCT  TGC  CCA  TCA.  To  ensure  the  accuracy,  the  internal 
reference reaction was performed using the same sample as used for target gene. The results were 
standardized with the formula: CTΔ = CTRef − CTTarget. The results were further converted to folds of 
target gene over the reference gene (F = 2
CTΔ).To compare the average values among different groups, 
ANOVA  (analysis  of  variance)  was  performed  to  determine  if  there  was  an  overall  significant 
difference. For the data to satisfy the initial ANOVA criterion, individual comparisons were performed Int. J. Mol. Sci. 2013, 14  6038 
 
with the use of a post hoc Bonferroni t test with the assumptions of a two-tail distribution and two 
samples with equal variance using SPSS software. 
4.5. In Vitro Proliferation Assay 
The cell proliferation assay was carried out using the CellTiter 96 Aqueous Non-Radioactive Cell 
Proliferation Assay kit (Promega, Madison, WI, USA) according to the manufacturer’s protocol. A 
total of 2 ×  10
4 cells from the HE4-overexpressing clones and from control clones were grown in  
48-well plates. Triplicate wells per clone were measured with absorbance at 490 nm (the absorbance at 
620 nm was used as background). Cell numbers were evaluated every 24 h from the first day (day 0) to 
the fifth day (day 4). The data were expressed as a ratio of DNA content between day X and day 0. 
Ratios  were  converted  to  a  logarithmic  scale,  and  the  cell  population  doubling  times  (PDT)  was 
calculated using the linear-regression model. For each experiment, triplicate wells were seeded and 
examined. Three independent experiments were performed and the average results were presented. 
4.6. Matrigel Invasion Assay 
The experiments were carried out following established protocols [43]. A thin layer of matrigel  
(40 μL of 8 mg/mL stock solution; Becton-Dickinson Labware, Bedford, MA, USA) was overlaid on 
the upper surface of the 6.5 mm transwell chambers (8-μm pore size; CoStar, Corning, NY, USA). The 
matrigel was allowed to solidify by incubating the plates for 4 h at room temperature. Culture medium 
was  added  to  the  bottom  chamber  of  the  transwells.  Stable  clones  for  HE4  overexpression  
(Ark2-HE4-C3,  -C7  and  -C12)  or  for  vector  control  (Ark2-PC1)  were  resuspended  in  0.2% 
BSA/optimal medium at a concentration of 2 ×  10
5 cells/mL, and 5 ×  10
4 cells were added to the top 
well of the transwell chambers. Following 6 h of incubation, cells that had not invaded through the 
matrigel were removed from the upper surface using cotton swabs. Cells that invaded through the 
matrigel and reached the lower surface of the filters were fixed in methanol and stained with a 0.2% 
solution of crystal violet. Invasion was quantified by counting the cell number under a Nikon Diaphot 
microscope equipped with a 16-square reticle. The surface area of this grid was 1 mm
2. Three separate 
fields were counted for each filter and the total numbers of cells were compared among experimental 
groups using the Student’s t test with the assumption of a two-tail distribution and two samples with 
equal variance. A difference of p < 0.05 was considered statistically significant.  
4.7. Soft Agar Colony Formation Assay 
The  assay  was  performed  with  the  use  of  a  commercial  kit  (cat  no.  ECM570,  Chemicon 
International  a  Serologicals  Company,  Emecula,  CA,  USA).  Briefly,  2500  cells  from  the  HE4 
overexpressing clones (HEC-1B-HE4-C4) or control clones (HEC-1B-PC10) were mixed with 0.4% 
soft agar and plated on a layer of 0.8% of bottom agar in 12-well plates. 300 μL of complete medium 
was added on the top of agar. Cells were fed twice a week, and the plates were incubated for 22 days at 
37  ° C  with  5%  CO2  until  colonies  formed.  Colonies  were  counted  under  the  microscope.  The 
experiment  was  repeated  three  times  and  the  average  numbers  of  colonies  were  calculated.  The 
difference between the HE4-overexpressing clones and the control ones was analyzed with the use of Int. J. Mol. Sci. 2013, 14  6039 
 
the Student’s t test, applying an assumption of a two-tail distribution and two samples with equal 
variance. A difference of p < 0.05 was considered statistically significant.  
4.8. Mouse Xenograft Model 
Six-week old female severe combined immunodeficient (SCID)/beige mice were purchased from 
Charles River Laboratories (Wilmington, MA, USA) and housed in the institutional animal facilities. 
All animal experiments were performed under protocols approved by the Mayo Clinic Institutional 
Animal Care and Use Committee. Two million EC tumor cells with HE4 stable expression (mixture of  
HEC-1B-HE4-C4, -C5 and -C12 clones) or transfected with control vector (mixture of HEC-1B-PC5 
and -PC10) were resuspended in 0.1 mL PBS and injected subcutaneously into the left flank of mice. 
Tumor  growth  was  monitored  every  four  days  from  the  ninth  day  after  tumor  implantation  by 
measuring the tumor axis. Tumor volumes were calculated by the formula V = 1/2a ×  b
2, where a is the 
longest  tumor  axis,  and  b  is  the  shortest
  tumor  axis.  On  day  30,  all  mice  were  sacrificed  by 
asphyxiation with CO2, and the tumors were dissected and weighed. Half of each tissue sample was 
fixed in 10% para-formaldehyde and preserved in paraffin blocks for further analysis. The other half 
were snap-frozen and stored at −80 ° C for RNA isolation.  
4.9. Detection of HE4 Expression in Tumor Tissues 
Tissue sections were prepared as described above. An immunohistochemistry accessory kit (Bethyl 
laboratories, Inc., Montgomery, TX, USA) was used to examine expression levels of HE4 according to 
the manufacturer’s protocol. Briefly, after deparaffinization and rehydration, the slides were incubated 
in 3% hydrogen peroxide/methanol to quench the endogenous peroxidase. Slides were then incubated 
in hot Epitope Retrieval Buffer (provided in kit) for 20 min at 90–96 ° C to recover epitopes. Non-specific 
reactions were blocked by incubating the sections with blocking reagent provided by the kit for 30 min 
at room temperature. 200  μL of human HE4 antibody (Signet Laboratory Inc., Dedham, MA, USA. 
Dilution 1:100) was applied to each slide and the slides were incubated at 4 ° C overnight. Slides were 
subsequently incubated with secondary anti-rabbit IHC antibody as provided by the kit, and peroxidase 
activity was visualized with 3,3'-diaminobenzidine (DAB) substrate. Counterstaining was performed 
with  hematoxylin.  The  stained  sections  from  eight  tumors  in  each  group  were  reviewed  and 
documented by a pathologist (D. Chen). HE4-positive staining was scored as 0 for negative, 1 for 
weak positive, 2 for positive, and 3 for strong positive in randomly selected high-power fields on the 
slide.  The  scores  from  the  two  groups  were  analyzed  by  the  statistician  using  the  Wilcoxon  
signed-rank test. p < 0.05 was considered statistically significant. 
4.10. Tumor Cell Proliferation Assay in Vivo 
Mice were injected with the Bromodeoxyuridine (BrdU) labeling reagent (Zymed Laboratories,
 
South San Francisco, CA, USA; 1  mL/100 gram body weight) intraperitoneally
 2 h before
 sacrifice. 
Tumor samples were dissected, fixed with 10% formalin overnight, and embedded in paraffin. Tissue
 
sections were cut and mounted on slides. Staining was performed using the anti-BrdU kit according to 
the manufacture’s protocols (Zymed Laboratories, South San Francisco, CA, USA). Briefly, following Int. J. Mol. Sci. 2013, 14  6040 
 
deparaffinization in xylene and
 rehydration with a graded series of ethanol, slides
 were blocked with 
3%  hydrogen  peroxide,  digested  with  trypsin,  and  blocked  with  1%  horse  serum  to  reduce  the  
non-specific staining. Tissue sections were stained with a biotinylated
 mouse monoclonal anti-BrdU 
antibody (Zymed Laboratories, South San Francisco, CA,  USA), and subsequently incubated with 
streptavidin peroxidase solution. The
 peroxidase activity was visualized with 3,3'-diaminobenzidine as 
substrate.
 Counterstaining was carried out with hematoxylin.
 The stained sections from 8 tumors for 
each group were reviewed. BrdU-positive nuclei were counted in 10 randomly selected
 high-power  
(40× ) fields for each slide. The percentage of the BrdU-positive nuclei was calculated and average 
values were obtained for each group. The percentage difference between the HE4-overexpressing mice 
and  the  control  mice  was  evaluated  with  the  Student’s  t  test  with  the  assumption  of  a  two-tail 
distribution and two samples with equal variance. Statistically significant was considered when p value 
is less than 0.05. 
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